Clinical Trials Browser

Phase 2 × Has announcements × ruxolitinib × Clear all

NCT02953678 2021-11-24

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Phase 2 Completed

71 enrolled 24 charts 1 FDA

Graft vs Host Disease